litlas
ログインアカウント作成

Jared Lunceford

2004–2024 年に発表

42
論文数
24,716
被引用数
38
h 指数
41
i10 指数

被引用数

Jared Lunceford の年別被引用数1945 年: 被引用 1 件2001 年: 被引用 1 件2003 年: 被引用 2 件2004 年: 被引用 1 件2005 年: 被引用 3 件2006 年: 被引用 1 件2007 年: 被引用 32 件2008 年: 被引用 58 件2009 年: 被引用 54 件2010 年: 被引用 51 件2011 年: 被引用 39 件2012 年: 被引用 35 件2013 年: 被引用 44 件2014 年: 被引用 48 件2015 年: 被引用 110 件2016 年: 被引用 349 件2017 年: 被引用 525 件2018 年: 被引用 486 件2019 年: 被引用 1,427 件2020 年: 被引用 1,833 件2021 年: 被引用 1,621 件2022 年: 被引用 1,218 件2023 年: 被引用 873 件2024 年: 被引用 1,149 件2025 年: 被引用 535 件2026 年: 被引用 13 件1946〜2000 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,782 件、この内訳の 26%中国: 引用元論文 2,368 件、この内訳の 16.2%イギリス: 引用元論文 692 件、この内訳の 4.7%イタリア: 引用元論文 651 件、この内訳の 4.5%日本: 引用元論文 651 件、この内訳の 4.5%ドイツ: 引用元論文 644 件、この内訳の 4.4%フランス: 引用元論文 614 件、この内訳の 4.2%スペイン: 引用元論文 493 件、この内訳の 3.4%カナダ: 引用元論文 460 件、この内訳の 3.2%韓国: 引用元論文 418 件、この内訳の 2.9%オーストラリア: 引用元論文 377 件、この内訳の 2.6%オランダ: 引用元論文 372 件、この内訳の 2.5%
0%26%その他 20.9%

機関

分野

  • Medicine76.3%
  • Biochemistry, Genetics and Molecular Biology11.9%
  • Immunology and Microbiology7.1%
  • Mathematics1.8%
  • Engineering0.8%
  • Computer Science0.5%
  • その他1.6%

トピック

  • Cancer Immunotherapy and Biomarkers21.4%
  • Immunotherapy and Immune Responses6.4%
  • CAR-T cell therapy research4%
  • Lung Cancer Treatments and Mutations3.8%
  • Ferroptosis and cancer prognosis3.4%
  • Immune Cell Function and Interaction3.3%
  • その他57.7%

共著者

全論文

検索で開く
  1. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

    著者: Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R. Kaufman, Andrew Albright, Jonathan D. Cheng, Shijun Kang, Veena Shankaran, Sarina A. Piha‐Paul, Jennifer H. Yearley, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan - Journal of Clinical Investigation 2017 被引用: 3,872

  2. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

    著者: Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi - New England Journal of Medicine 2015 被引用: 6,228

  3. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

    著者: Răzvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer H. Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn, Chunsheng Zhang, Jared Lunceford, Andrew K. Joe, Jonathan D. Cheng, Andrea L. Webber, Nageatte Ibrahim, Elizabeth R. Plimack, Patrick A. Ott, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan, Joanne E. Tomassini, Andrey Loboda, David R. Kaufman - Science 2018 被引用: 2,380

  4. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

    著者: Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul, Albiruni R. Abdul Razak, Jaafar Bennouna, Jean‐Charles Soria, Hope S. Rugo, Roger B. Cohen, Bert H. O’Neil, Janice M. Mehnert, Juanita Lopez, Toshihiko Doi, Emilie M.J. van Brummelen, Răzvan Cristescu, Ping Yang, Kenneth Emancipator, Karen Stein, Mark Ayers, Andrew K. Joe, Jared Lunceford - Journal of Clinical Oncology 2018 被引用: 992

  5. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

    著者: Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph P. Eder, Karl Heath, Terrill K. McClanahan, Jared Lunceford, Christine K. Gause, Jonathan D. Cheng, Laura Q.M. Chow - The Lancet Oncology 2016 被引用: 1,740

  6. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

    著者: Jennifer H. Yearley, Christopher J. Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan Juco, Jared Lunceford, Jonathan D. Cheng, Laura Q.M. Chow, Tanguy Y. Seiwert, Masahisa Handa, Joanne E. Tomassini, Terrill K. McClanahan - Clinical Cancer Research 2017 被引用: 604

  7. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    著者: Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel V.T. Catenacci, Shilpa Gupta, Joseph P. Eder, Talia Golan, Dung T. Le, Barbara Burtness, Autumn J. McRee, Chia‐Chi Lin, Kumudu Pathiraja, Jared Lunceford, Kenneth Emancipator, Jonathan Juco, Minori Koshiji, Yung‐Jue Bang - The Lancet Oncology 2016 被引用: 1,131

  8. Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

    著者: Adil Daud, Jedd D. Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S. Weber, Antoni Ribas, F. Stephen Hodi, Anthony M. Joshua, Richard Kefford, Peter Hersey, Richard W. Joseph, Tara C. Gangadhar, Roxana Dronca, Amita Patnaik, Hassane M. Zarour, Charlotte Roach, Grant Toland, Jared Lunceford, Xiaoyun Li, Kenneth Emancipator, Marisa Dolled‐Filhart, Sunyu Kang, Scot Ebbinghaus, Omid Hamid - Journal of Clinical Oncology 2016 被引用: 678

  9. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

    著者: Karina Kulangara, Nancy R. Zhang, Ellie Corigliano, Lindsay Guerrero, Stephanie Waldroup, Dipeshkumar Jaiswal, Malinka Jansson, Supriya Shah, Debra Hanks, Jiangdian Wang, Jared Lunceford, Mary J. Savage, Jonathan Juco, Kenneth Emancipator - Archives of Pathology & Laboratory Medicine 2018 被引用: 536

  10. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

    著者: Răzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Lei Xu, Xiao Qiao Liu, Andrey Loboda, Lixin Lang, Fan Jin, Eric H. Rubin, Alexandra Snyder, Jared Lunceford - Journal for ImmunoTherapy of Cancer 2022 被引用: 161

  11. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

    著者: Manish A. Shah, Takashi Kojima, Daniel Hochhauser, Peter C. Enzinger, Judith Raimbourg, Antoine Hollebecque, Florian Lordick, Sung‐Bae Kim, Masahiro Tajika, Heung Tae Kim, A. Craig Lockhart, Hendrik-Tobias Arkenau, Farid El-Hajbi, Mukul Gupta, Per Pfeiffer, Qi Liu, Jared Lunceford, Soonmo Peter Kang, Pooja Bhagia, Ken Kato - JAMA Oncology 2018 被引用: 519

  12. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

    著者: Jared Lunceford, Marie Davidian - Statistics in Medicine 2004 被引用: 1,696

  13. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

    著者: Tony Mok, G. Lopes, Byoung Chul Cho, Dariusz M. Kowalski, Kazuo Kasahara, Yi‐Long Wu, Gilberto de Castro, H.Z. Turna, Răzvan Cristescu, Deepti Aurora-Garg, Andrey Loboda, Jared Lunceford, Julie Kobie, Mark Ayers, M. Catherine Pietanza, Bilal Piperdi, Roy S. Herbst - Annals of Oncology 2023 被引用: 71

  14. Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types

    著者: Răzvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, Andrew Albright, Julie Kobie, Lingkang Huang, Qing Zhao, Anran Wang, Hua Ma, Zheng Cao, Michael Morrissey, Antoni Ribas, Petros Grivas, David W. Cescon, Terrill K. McClanahan, Alexandra Snyder, Mark Ayers, Jared Lunceford, Andrey Loboda - Clinical Cancer Research 2021 被引用: 74

  15. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

    著者: Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Răzvan Cristescu, Jonathan D. Cheng, Ranee Mehra - Journal for ImmunoTherapy of Cancer 2022 被引用: 96

  16. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis

    著者: Sherene Loi, Roberto Salgado, Peter Schmid, Javier Cortés, David W. Cescon, Eric P. Winer, Deborah Toppmeyer, Hope S. Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R. Tan, Yuan Sun, Vassiliki Karantza, Anran Wang, Lingkang Huang, Assieh Saadatpour, Răzvan Cristescu, Jennifer H. Yearley, Jared Lunceford, Petar Jelinic, Sylvia Adams - JCO Precision Oncology 2023 被引用: 56

  17. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    著者: Marina Chiara Garassino, Shirish M. Gadgeel, Silvia Novello, Balázs Halmos, Enriqueta Felip, Giovanna Speranza, Rina Hui, Edward B. Garon, Hidehito Horinouchi, Shunichi Sugawara, Delvys Rodríguez‐Abreu, Martin Reck, Răzvan Cristescu, Deepti Aurora-Garg, Andrey Loboda, Jared Lunceford, Julie Kobie, Mark Ayers, Bilal Piperdi, M. Catherine Pietanza, Luis Paz‐Ares - JTO Clinical and Research Reports 2022 被引用: 42

  18. First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

    著者: Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror - Clinical Cancer Research 2021 被引用: 68

  19. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

    著者: Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas - Clinical Cancer Research 2022 被引用: 48

  20. Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma

    著者: Toshihiko Doi, Sarina A. Piha‐Paul, Shadia I. Jalal, Sanatan Saraf, Jared Lunceford, Minori Koshiji, Jaafar Bennouna - Journal of Clinical Oncology 2017 被引用: 323

  21. KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

    著者: Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Enriqueta Felip, Emilio Esteban, G. Speranza, Martin Reck, Rina Hui, Michael Boyer, Edward B. Garon, Hidehito Horinouchi, Răzvan Cristescu, Deepti Aurora-Garg, Jared Lunceford, Julie Kobie, Mark Ayers, Bilal Piperdi, M. Catherine Pietanza, Marina Chiara Garassino - Annals of Oncology 2019 被引用: 82

  22. Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

    著者: Ian E. Krop, Tim Demuth, Tina Guthrie, Patrick Y. Wen, Warren Mason, Prakash Chinnaiyan, Nicholas Butowski, Morris D. Groves, Santosh Kesari, Steven J. Freedman, Samuel C. Blackman, James Watters, Andrey Loboda, Alexei A. Podtelezhnikov, Jared Lunceford, Cong Chen, Maxine Giannotti, Jeremy Hing, Robert A. Beckman, Patricia LoRusso - Journal of Clinical Oncology 2012 被引用: 317

  23. Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial

    著者: Thomas Powles, Yen‐Hwa Chang, Yoshiaki Yamamoto, José F. Muñoz, Felipe Reyes-Cosmelli, Avivit Peer, Graham Cohen, Evan Y. Yu, Anja Lorch, Abhishek Bavle, Blanca Homet Moreno, Julia F. Markensohn, Mackenzie Edmondson, Chen Cai, Răzvan Cristescu, Carol E. Peña, Jared Lunceford, Şeyda Gündüz - Nature Medicine 2024 被引用: 34

  24. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

    著者: Roy S. Herbst, Gilberto Lopes, Dariusz M. Kowalski, Kazuo Kasahara, Yuanqiang Wu, Gilberto de Castro, Byoung Chul Cho, H.Z. Turna, Răzvan Cristescu, Deepti Aurora-Garg, Jared Lunceford, Julie Kobie, Mark Ayers, M. Catherine Pietanza, Bilal Piperdi, Tony Mok - Annals of Oncology 2019 被引用: 92